Personalized Medicine: Panacea or Pipedream?
by Jeffrey N. Gibbs, Principal in the law firm of Hyman, Phelps & McNamara, PC,
Washington, DC
Personalized Medicine: A Patient-Centered Perspective
by M. Carolina Hinestrosa, Executive Vice President for Programs and Planning, National Breast Cancer Coalition, Washington, DC
The Ever-Evolving Role of “Companion Diagnostics”
by Randy Prebula, Director of Regulatory Science at the law firm of Hogan & Hartson, LLP, Washington, DC
Personalized Medicine: The Role of Laboratories
by Victoria M. Pratt, Chief Director, Molecular Genetics at Quest Diagnostics, Nichols Institute, Chantilly, VA, and clinical Practice Committee Chair of the Association for Molecular Pathology
and
S. Terence Dunn, Associate Professor, Pathology Department and Director of the Molecular Pathology Laboratory, University of Oklahoma Health Sciences Center, Oklahoma City, OK and Secretary/Treasurer, Publications Committee Chair, Association for Molecular Pathology
and
Karen E. Weck, Associate Professor of Pathology and Laboratory Medicine and Director, Molecular Genetics, University of North Carolina, Chapel Hill, NC and past Program Committee Chair, Association for Molecular Pathology
Collecting and Testing Samples for Pharmacogenomic Research: Issues for Manufacturers of Drug and Biological Products
by Grail Sipes, Partner in the law firm of Covington & Burling LLP, Washington, DC
IP Considerations in Early Biomarker Development in the Personalized Medicine Age
by Peter Keeling, CEO, Diaceutics
and
Mollie Roth, Corporate Counsel, Vice President of Business Development, Diaceutics and Visiting Faculty Fellow, Center for the Study of Law, Science and Technology, Sandra Day O’Connor College of Law, Arizona State University
Research, Policy Advances Needed to Fulfill Promise of Genetic Medicine,
Experts Say at AAAs
by Earl Lane, Senior Communications Officer, AAAS Office of Public Programs, Washington, DC
